Digital Health Global

FEBRUARY 19, 2024

This expansion mirrors a trend identified in an industry report jointly published by Biofourmis and HealthXL last year, predicting widespread adoption of digital endpoints by pharmaceutical companies in drug development programs by 2030.

Pharmaceuticals 166

Pharmaceuticals Leadership Drug Development Digital Health 166

Healthcare IT Today

DECEMBER 27, 2022

Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development. “A For more information about Fujifilm’s Sustainable Value Plan 2030, click here.

Pharmaceuticals 59

Pharmaceuticals Drug Development Medical Technology Healthcare IT 59

Lloyd Price

FEBRUARY 22, 2024

Reasons for Low Investment: High regulatory hurdles: Drug development for pain is historically challenging with a high failure rate due to complex pain mechanisms and stringent regulatory requirements. Here's a breakdown: Overall Pain Management Market: The global pain management drugs market was valued at USD 78.66 until 2032.

Pain management 56

Pain management Mental health Telehealth healthcare technology 56

Xealth

JUNE 27, 2023

billion by 2030. Its interest in DTx exists specifically in remote patient monitoring because of the potential to provide valuable insights throughout drug development life cycles. Big Pharma is driving much of the speculation.

Digital Health 52

Digital Health Drug Development Pharmaceuticals EHR 52